1 active not recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
Follow Wenjun Cheng: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer Drug: Anlotinib, Drug: Carboplatin/Paclitaxel - Ovarian Neoplasms, Fallopian Tube Neoplasms | Phase 2 | Active not recruiting | Wenjun Cheng | 56 | 2021-08-24 | 2024-07-03 |
Carcinoma (1) · Carcinoma, Ovarian Epithelial (1) · Endocrine System Diseases (1) · Fallopian Tube Neoplasms (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Ovarian Diseases (1) · Ovarian Neoplasms (1)
CP protocol (1) · anlotinib (1)
China (1)